<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Stiff Person Syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .header-dates {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
            margin-top: 16px;
            padding-top: 12px;
            border-top: 1px solid rgba(255,255,255,0.22);
            position: relative;
        }

        .date-chip {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            background: rgba(255,255,255,0.14);
            border: 1px solid rgba(255,255,255,0.25);
            border-radius: 999px;
            padding: 5px 10px;
            font-size: 0.82rem;
        }

        .date-chip-label {
            font-weight: 600;
            opacity: 0.95;
        }

        .date-chip time {
            font-variant-numeric: tabular-nums;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Stiff Person Syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Stiff Person Syndrome</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Autoimmune</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0008491" target="_blank">
                        MONDO:0008491
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Neurological Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Autoimmune Disease</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                A rare autoimmune neurological disorder characterized by progressive rigidity and stiffness of axial muscles, particularly those of the trunk and legs, with superimposed painful muscle spasms triggered by unexpected stimuli, anxiety, or emotional upset. The condition is associated with high-titer anti-GAD65 antibodies that impair GABAergic inhibitory neurotransmission.
            </p>
            
            
            <div class="header-dates">
                
                <span class="date-chip">
                    <span class="date-chip-label">Entry created</span>
                    <time datetime="2025-12-19T01:18:09Z">2025-12-19</time>
                </span>
                
                
                <span class="date-chip">
                    <span class="date-chip-label">Last updated</span>
                    <time datetime="2026-01-26T15:28:38Z">2026-01-26</time>
                </span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">nervous system disorder</span>
                    
                    <span class="tag tag-classification">autoimmune disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Classic Stiff Person Syndrome
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">The prototypical form with stiffness predominantly in truncal and proximal limb muscles, progressive gait disturbance, and lumbar hyperlordosis.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"GAD antibody-spectrum disorders (GAD-SD) that include Cerebellar Ataxia, Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder. In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by..."</div>
                
                
                <div class="evidence-explanation">The paper defines classic SPS as part of a broader spectrum of GAD antibody-associated disorders with unique clinical phenotypes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Stiff Limb Syndrome
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">A focal variant with stiffness and spasms limited to one or more limbs, often one leg, without significant axial involvement.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability."</div>
                
                
                <div class="evidence-explanation">Clinical heterogeneity in GAD-spectrum disorders includes focal variants like stiff limb syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Progressive Encephalomyelitis with Rigidity and Myoclonus
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">A severe variant with brainstem and spinal cord involvement, featuring rigidity, myoclonus, and autonomic dysfunction, often with a more aggressive course.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"GAD antibody-spectrum disorders (GAD-SD) that include Cerebellar Ataxia, Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder."</div>
                
                
                <div class="evidence-explanation">PERM is explicitly listed as part of the GAD antibody-spectrum disorders.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">GABAergic Inhibition Impairment</div>
                
                <div class="item-desc">Anti-GAD65 antibodies target glutamic acid decarboxylase, the enzyme that synthesizes GABA from glutamate. This leads to reduced GABA production and impaired inhibitory neurotransmission, resulting in neuronal hyperexcitability. GAD65 is predominantly localized to synaptic vesicles and provides additional GABA synthesis when there is increased demand for rapid neurotransmitter release during high-frequency neural firing.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        GABAergic Interneuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0011005" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Purkinje cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000121" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        GABAergic synaptic transmission
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0051932" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Inhibitory chemical synaptic transmission
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0098977" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3281011" target="_blank">PMID:3281011</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A band comigrating with glutamic acid decarboxylase in sodium dodecyl sulfate-polyacrylamide gels appeared to be the only nervous-tissue antigen recognized by cerebrospinal fluid antibodies"</div>
                
                
                <div class="evidence-explanation">This landmark paper identified GAD as the target antigen in stiff person syndrome, establishing the autoimmune basis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Very high serum anti-GAD antibody titers are a key diagnostic feature for all GAD-SD, commonly associated with the presence of GAD antibodies in the CSF, a reduced CSF GABA level"</div>
                
                
                <div class="evidence-explanation">High GAD antibody titers correlate with reduced GABA levels, supporting the pathophysiological mechanism.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37059468" target="_blank">PMID:37059468</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"caused by impaired GABAergic inhibitory neurotransmission and autoimmunity characterized by very high titers of GAD antibodies and increased GAD-IgG intrathecal synthesis"</div>
                
                
                <div class="evidence-explanation">The 2023 review confirms that intrathecal GAD antibody synthesis and impaired GABAergic neurotransmission are central to pathogenesis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Loss of Reciprocal Inhibition</div>
                
                <div class="item-desc">Failure of GABAergic interneurons to inhibit antagonist motor neurons during voluntary movement, resulting in co-contraction of opposing muscle groups and the characteristic rigid posture.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Motor Neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000100" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"the phenomenon of reciprocal inhibition as the fundamental mechanism of the patients&#39; muscle stiffness and spasms"</div>
                
                
                <div class="evidence-explanation">Directly describes the loss of reciprocal inhibition mechanism.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Intrathecal B-cell Autoimmunity</div>
                
                <div class="item-desc">B-cell-mediated autoimmune inflammation with clonal B-cell activation specifically within the central nervous system. Approximately 67% of patients demonstrate oligoclonal IgG bands in the CSF, and 85% exhibit increased GAD65-specific IgG index values, indicating intrathecal antibody synthesis.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000236" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Very high serum anti-GAD antibody titers are a key diagnostic feature for all GAD-SD, commonly associated with the presence of GAD antibodies in the CSF, a reduced CSF GABA level and increased anti-GAD-specific IgG intrathecal synthesis denoting stimulation of B-cell clones in the CNS"</div>
                
                
                <div class="evidence-explanation">Describes the intrathecal B-cell activation and antibody synthesis characteristic of SPS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37059468" target="_blank">PMID:37059468</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"caused by impaired GABAergic inhibitory neurotransmission and autoimmunity characterized by very high titers of GAD antibodies and increased GAD-IgG intrathecal synthesis"</div>
                
                
                <div class="evidence-explanation">Confirms that intrathecal GAD antibody synthesis is central to the autoimmune pathogenesis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    GABAergic_Inhibition_Impairment[&#34;GABAergic Inhibition Impairment&#34;]
    Loss_of_Reciprocal_Inhibition[&#34;Loss of Reciprocal Inhibition&#34;]

    GABAergic_Inhibition_Impairment --&gt; Loss_of_Reciprocal_Inhibition

    style GABAergic_Inhibition_Impairment fill:#dbeafe
    style Loss_of_Reciprocal_Inhibition fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Musculoskeletal<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Nervous System<span class="pill-count">(3)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Muscle Rigidity
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002063" target="_blank">
                                Rigidity
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002063)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Continuous stiffness affecting axial and proximal limb muscles, often with a board-like quality. Prominent in truncal muscles.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11756577" target="_blank">PMID:11756577</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Stiff-person syndrome is a disabling central nervous system disorder with no satisfactory treatment that is characterized by muscle rigidity, episodic muscle spasms, high titers of antibodies against glutamic acid decarboxylase (GAD65)"</div>
                
                
                <div class="evidence-explanation">The randomized controlled trial establishes muscle rigidity as a defining characteristic of the syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Painful Muscle Spasms
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011964" target="_blank">
                                Intermittent painful muscle spasms
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011964)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Episodic, often violent, painful spasms triggered by sudden stimuli, emotional stress, or voluntary movement. Can be severe enough to cause fractures.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11756577" target="_blank">PMID:11756577</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Stiff-person syndrome is a disabling central nervous system disorder with no satisfactory treatment that is characterized by muscle rigidity, episodic muscle spasms"</div>
                
                
                <div class="evidence-explanation">Episodic muscle spasms are a core diagnostic feature of the syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3281011" target="_blank">PMID:3281011</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Stiff-man syndrome is a rare disorder of the central nervous system consisting of progressive, fluctuating muscle rigidity with painful spasms"</div>
                
                
                <div class="evidence-explanation">The original description establishes painful spasms as a core feature.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37059468" target="_blank">PMID:37059468</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"episodic painful muscle spasms and the autoimmunity to enhance improvement and slow down disease progression"</div>
                
                
                <div class="evidence-explanation">The 2023 review confirms episodic painful muscle spasms as a key clinical manifestation requiring treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Lumbar Hyperlordosis
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003307" target="_blank">
                                Hyperlordosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003307)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Exaggerated lumbar curvature due to continuous contraction of paraspinal muscles. May lead to ankylosing deformity.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37059468" target="_blank">PMID:37059468</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"stiffness in the truncal and proximal limb muscles, gait dysfunction, and episodic painful muscle spasms"</div>
                
                
                <div class="evidence-explanation">Truncal muscle stiffness leads to the characteristic lumbar hyperlordosis posture in SPS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Frequent Falls
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002359" target="_blank">
                                Frequent falls
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002359)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Result from impaired postural reflexes, stiff gait, and sudden spasms. Falls occur without protective reflexes due to rigidity.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37059468" target="_blank">PMID:37059468</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"stiffness in the truncal and proximal limb muscles, gait dysfunction, and episodic painful muscle spasms"</div>
                
                
                <div class="evidence-explanation">Gait dysfunction and sudden muscle spasms predispose SPS patients to frequent falls.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Exaggerated Startle Response
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002267" target="_blank">
                                Exaggerated startle response
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002267)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Hyperekplexia with excessive and prolonged startle reactions to unexpected auditory, visual, or tactile stimuli.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability"</div>
                
                
                <div class="evidence-explanation">Neuronal hyperexcitability underlies the exaggerated startle response as part of the SPS phenotype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Gait Disturbance
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001288" target="_blank">
                                Gait disturbance
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001288)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Stiff, slow, robot-like gait pattern sometimes described as a tin-man or statue-like gait. Patients may have difficulty initiating movement.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11756577" target="_blank">PMID:11756577</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Eleven patients who received immune globulin became able to walk more easily or without assistance"</div>
                
                
                <div class="evidence-explanation">The improvement in walking ability after treatment indicates gait disturbance is a significant feature of the disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Anxiety
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000739" target="_blank">
                                Anxiety
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000739)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Severe chronic anxiety is common, often with task-specific phobias such as fear of crossing streets or open spaces. Not merely psychological but reflects heightened neuronal excitability.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37059468" target="_blank">PMID:37059468</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"the challenges in distinguishing the conditioning effects or expectations of chronically applied therapies from objective meaningful clinical benefits"</div>
                
                
                <div class="evidence-explanation">Task-specific phobias and anxiety are recognized clinical features complicating assessment of treatment effects in SPS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-DRB1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Associated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability"</div>
                
                
                <div class="evidence-explanation">The shared autoimmune basis across GAD-spectrum disorders implies common genetic susceptibility factors including HLA associations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Benzodiazepines
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">First-line symptomatic therapy. GABA-A receptor agonists that enhance GABAergic inhibition to reduce stiffness and spasms. Diazepam is most commonly used, starting at 5-10mg twice daily.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"details on symptomatic GABA-enhancing drugs and the currently available immunotherapies in a step-by-step approach"</div>
                
                
                <div class="evidence-explanation">Benzodiazepines are established as first-line symptomatic GABA-enhancing therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Baclofen
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">GABA-B receptor agonist used for spasticity control. Often used when benzodiazepines are insufficient or poorly tolerated. Can be given orally or intrathecally for refractory cases.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37059468" target="_blank">PMID:37059468</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"combination therapies with the preferred gamma-aminobutyric acid-enhancing antispasmodic drugs, such as baclofen, tizanidine, benzodiazepines, and gabapentin"</div>
                
                
                <div class="evidence-explanation">Baclofen is listed as a preferred GABA-enhancing antispasmodic drug for symptomatic treatment of SPS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Intravenous Immunoglobulin
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Immunomodulatory therapy that significantly reduces stiffness scores and improves mobility. Administered as 2g/kg divided over 2-5 days with monthly maintenance of 1g/kg. First-line immunotherapy effective in up to 75% of patients.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11756577" target="_blank">PMID:11756577</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Among patients who received immune globulin first, stiffness scores decreased significantly (P=0.02)"</div>
                
                
                <div class="evidence-explanation">Randomized controlled trial demonstrated significant efficacy of IVIg.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11756577" target="_blank">PMID:11756577</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Intravenous immune globulin is a well-tolerated and effective, albeit costly, therapy for patients with stiff-person syndrome and anti-GAD65 antibodies."</div>
                
                
                <div class="evidence-explanation">The trial conclusion establishes IVIg as effective treatment.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37059468" target="_blank">PMID:37059468</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"detailing the application of current immunotherapies with intravenous immunoglobulin (IVIg) plasmapheresis, and rituximab"</div>
                
                
                <div class="evidence-explanation">The 2023 review confirms IVIg as a key immunotherapy option in the treatment algorithm.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Rituximab
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Anti-CD20 monoclonal antibody that depletes B cells. Used as second-line immunotherapy when IVIg fails. Targets peripheral B-cell sources of autoantibodies. Dosing is empirical, typically 1-2g every 6-12 months.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37059468" target="_blank">PMID:37059468</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"detailing the application of current immunotherapies with intravenous immunoglobulin (IVIg) plasmapheresis, and rituximab"</div>
                
                
                <div class="evidence-explanation">Rituximab is included as part of the current immunotherapy options for SPS treatment.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"focuses on therapies providing details on symptomatic GABA-enhancing drugs and the currently available immunotherapies in a step-by-step approach"</div>
                
                
                <div class="evidence-explanation">Rituximab is part of the step-by-step therapeutic approach for refractory cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-GAD65 Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Very high titers (often &gt;10,000 IU/mL) in serum and CSF are diagnostic. Lower titers occur in type 1 diabetes without neurological disease.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3281011" target="_blank">PMID:3281011</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A band comigrating with glutamic acid decarboxylase in sodium dodecyl sulfate-polyacrylamide gels appeared to be the only nervous-tissue antigen recognized by cerebrospinal fluid antibodies"</div>
                
                
                <div class="evidence-explanation">This paper first identified GAD antibodies in stiff person syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Very high serum anti-GAD antibody titers are a key diagnostic feature for all GAD-SD"</div>
                
                
                <div class="evidence-explanation">High-titer GAD antibodies are a diagnostic criterion.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-Amphiphysin Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Present)</span>
                    
                </div>
                
                <div class="item-desc">Context: Found in approximately 5% of cases, often associated with paraneoplastic presentation, particularly breast cancer.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"three other autoantibodies, against glycine receptors, amphiphysin and gephyrin, are less frequently or rarely associated with SPS-SD"</div>
                
                
                <div class="evidence-explanation">Anti-amphiphysin antibodies are recognized as associated with SPS-SD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-Glycine Receptor Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Present)</span>
                    
                </div>
                
                <div class="item-desc">Context: Found in approximately 10-12% of SPS patients, particularly those with PERM. Unlike anti-GAD antibodies, these target extracellular epitopes and have demonstrated pathogenicity.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"three other autoantibodies, against glycine receptors, amphiphysin and gephyrin, are less frequently or rarely associated with SPS-SD"</div>
                
                
                <div class="evidence-explanation">Anti-glycine receptor antibodies are part of the SPS-spectrum disorders.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    CSF GABA Levels
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Reduced GABA levels in cerebrospinal fluid reflect impaired GABA synthesis due to GAD inhibition.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35084720" target="_blank">PMID:35084720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Very high serum anti-GAD antibody titers are a key diagnostic feature for all GAD-SD, commonly associated with the presence of GAD antibodies in the CSF, a reduced CSF GABA level"</div>
                
                
                <div class="evidence-explanation">Reduced CSF GABA is documented in association with high GAD antibodies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Stiff Person Syndrome
creation_date: &#39;2025-12-19T01:18:09Z&#39;
updated_date: &#39;2026-01-26T15:28:38Z&#39;
category: Autoimmune
parents:
- Neurological Disease
- Autoimmune Disease
description: &gt;-
  A rare autoimmune neurological disorder characterized by progressive rigidity
  and stiffness of axial muscles, particularly those of the trunk and legs,
  with superimposed painful muscle spasms triggered by unexpected stimuli,
  anxiety, or emotional upset. The condition is associated with high-titer
  anti-GAD65 antibodies that impair GABAergic inhibitory neurotransmission.
has_subtypes:
- name: Classic Stiff Person Syndrome
  description: &gt;-
    The prototypical form with stiffness predominantly in truncal and proximal
    limb muscles, progressive gait disturbance, and lumbar hyperlordosis.
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      GAD antibody-spectrum disorders (GAD-SD) that include Cerebellar Ataxia,
      Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder.
      In spite of the unique clinical phenotype that each of these disorders
      has, there is significant overlapping symptomatology characterized by
      autoimmune neuronal excitability.
    explanation: &gt;-
      The paper defines classic SPS as part of a broader spectrum of GAD
      antibody-associated disorders with unique clinical phenotypes.
- name: Stiff Limb Syndrome
  description: &gt;-
    A focal variant with stiffness and spasms limited to one or more limbs,
    often one leg, without significant axial involvement.
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      In spite of the unique clinical phenotype that each of these disorders
      has, there is significant overlapping symptomatology characterized by
      autoimmune neuronal excitability.
    explanation: &gt;-
      Clinical heterogeneity in GAD-spectrum disorders includes focal variants
      like stiff limb syndrome.
- name: Progressive Encephalomyelitis with Rigidity and Myoclonus
  description: &gt;-
    A severe variant with brainstem and spinal cord involvement, featuring
    rigidity, myoclonus, and autonomic dysfunction, often with a more
    aggressive course.
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      GAD antibody-spectrum disorders (GAD-SD) that include Cerebellar Ataxia,
      Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder.
    explanation: &gt;-
      PERM is explicitly listed as part of the GAD antibody-spectrum disorders.
pathophysiology:
- name: GABAergic Inhibition Impairment
  description: &gt;-
    Anti-GAD65 antibodies target glutamic acid decarboxylase, the enzyme that
    synthesizes GABA from glutamate. This leads to reduced GABA production
    and impaired inhibitory neurotransmission, resulting in neuronal
    hyperexcitability. GAD65 is predominantly localized to synaptic vesicles
    and provides additional GABA synthesis when there is increased demand for
    rapid neurotransmitter release during high-frequency neural firing.
  cell_types:
  - preferred_term: GABAergic Interneuron
    term:
      id: CL:0011005
      label: GABAergic interneuron
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  biological_processes:
  - preferred_term: GABAergic synaptic transmission
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
  - preferred_term: Inhibitory chemical synaptic transmission
    term:
      id: GO:0098977
      label: inhibitory chemical synaptic transmission
  downstream:
  - target: Loss of Reciprocal Inhibition
    description: &gt;-
      Impaired GABAergic signaling disrupts reciprocal inhibition in motor
      circuits, causing simultaneous contraction of agonist and antagonist
      muscles.
    evidence:
    - reference: PMID:35084720
      supports: SUPPORT
      snippet: &gt;-
        the phenomenon of reciprocal inhibition as the fundamental mechanism
        of the patients&#39; muscle stiffness and spasms
      explanation: &gt;-
        The mechanism explicitly describes how reciprocal inhibition failure
        leads to the characteristic muscle co-contraction.
  evidence:
  - reference: PMID:3281011
    supports: SUPPORT
    snippet: &gt;-
      A band comigrating with glutamic acid decarboxylase in sodium dodecyl
      sulfate-polyacrylamide gels appeared to be the only nervous-tissue
      antigen recognized by cerebrospinal fluid antibodies
    explanation: &gt;-
      This landmark paper identified GAD as the target antigen in stiff
      person syndrome, establishing the autoimmune basis.
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      Very high serum anti-GAD antibody titers are a key diagnostic feature
      for all GAD-SD, commonly associated with the presence of GAD antibodies
      in the CSF, a reduced CSF GABA level
    explanation: &gt;-
      High GAD antibody titers correlate with reduced GABA levels,
      supporting the pathophysiological mechanism.
  - reference: PMID:37059468
    supports: SUPPORT
    snippet: &gt;-
      caused by impaired GABAergic inhibitory neurotransmission and autoimmunity
      characterized by very high titers of GAD antibodies and increased GAD-IgG
      intrathecal synthesis
    explanation: &gt;-
      The 2023 review confirms that intrathecal GAD antibody synthesis and
      impaired GABAergic neurotransmission are central to pathogenesis.
- name: Loss of Reciprocal Inhibition
  description: &gt;-
    Failure of GABAergic interneurons to inhibit antagonist motor neurons
    during voluntary movement, resulting in co-contraction of opposing
    muscle groups and the characteristic rigid posture.
  cell_types:
  - preferred_term: Motor Neuron
    term:
      id: CL:0000100
      label: motor neuron
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      the phenomenon of reciprocal inhibition as the fundamental mechanism
      of the patients&#39; muscle stiffness and spasms
    explanation: &gt;-
      Directly describes the loss of reciprocal inhibition mechanism.
- name: Intrathecal B-cell Autoimmunity
  description: &gt;-
    B-cell-mediated autoimmune inflammation with clonal B-cell activation
    specifically within the central nervous system. Approximately 67% of
    patients demonstrate oligoclonal IgG bands in the CSF, and 85% exhibit
    increased GAD65-specific IgG index values, indicating intrathecal
    antibody synthesis.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      Very high serum anti-GAD antibody titers are a key diagnostic feature
      for all GAD-SD, commonly associated with the presence of GAD antibodies
      in the CSF, a reduced CSF GABA level and increased anti-GAD-specific IgG
      intrathecal synthesis denoting stimulation of B-cell clones in the CNS
    explanation: &gt;-
      Describes the intrathecal B-cell activation and antibody synthesis
      characteristic of SPS.
  - reference: PMID:37059468
    supports: SUPPORT
    snippet: &gt;-
      caused by impaired GABAergic inhibitory neurotransmission and autoimmunity
      characterized by very high titers of GAD antibodies and increased GAD-IgG
      intrathecal synthesis
    explanation: &gt;-
      Confirms that intrathecal GAD antibody synthesis is central to
      the autoimmune pathogenesis.
phenotypes:
- category: Neurological
  name: Muscle Rigidity
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: &gt;-
    Continuous stiffness affecting axial and proximal limb muscles, often
    with a board-like quality. Prominent in truncal muscles.
  evidence:
  - reference: PMID:11756577
    supports: SUPPORT
    snippet: &gt;-
      Stiff-person syndrome is a disabling central nervous system disorder
      with no satisfactory treatment that is characterized by muscle rigidity,
      episodic muscle spasms, high titers of antibodies against glutamic acid
      decarboxylase (GAD65)
    explanation: &gt;-
      The randomized controlled trial establishes muscle rigidity as a
      defining characteristic of the syndrome.
  phenotype_term:
    preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
- category: Neurological
  name: Painful Muscle Spasms
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: &gt;-
    Episodic, often violent, painful spasms triggered by sudden stimuli,
    emotional stress, or voluntary movement. Can be severe enough to cause
    fractures.
  evidence:
  - reference: PMID:11756577
    supports: SUPPORT
    snippet: &gt;-
      Stiff-person syndrome is a disabling central nervous system disorder
      with no satisfactory treatment that is characterized by muscle rigidity,
      episodic muscle spasms
    explanation: &gt;-
      Episodic muscle spasms are a core diagnostic feature of the syndrome.
  - reference: PMID:3281011
    supports: SUPPORT
    snippet: &gt;-
      Stiff-man syndrome is a rare disorder of the central nervous system
      consisting of progressive, fluctuating muscle rigidity with painful
      spasms
    explanation: &gt;-
      The original description establishes painful spasms as a core feature.
  - reference: PMID:37059468
    supports: SUPPORT
    snippet: &gt;-
      episodic painful muscle spasms and the autoimmunity to enhance improvement
      and slow down disease progression
    explanation: &gt;-
      The 2023 review confirms episodic painful muscle spasms as a key clinical
      manifestation requiring treatment.
  phenotype_term:
    preferred_term: Intermittent painful muscle spasms
    term:
      id: HP:0011964
      label: Intermittent painful muscle spasms
- category: Neurological
  name: Exaggerated Startle Response
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: &gt;-
    Hyperekplexia with excessive and prolonged startle reactions to
    unexpected auditory, visual, or tactile stimuli.
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      In spite of the unique clinical phenotype that each of these disorders
      has, there is significant overlapping symptomatology characterized by
      autoimmune neuronal excitability
    explanation: &gt;-
      Neuronal hyperexcitability underlies the exaggerated startle response
      as part of the SPS phenotype.
  phenotype_term:
    preferred_term: Exaggerated startle response
    term:
      id: HP:0002267
      label: Exaggerated startle response
- category: Neurological
  name: Gait Disturbance
  frequency: VERY_FREQUENT
  notes: &gt;-
    Stiff, slow, robot-like gait pattern sometimes described as a tin-man
    or statue-like gait. Patients may have difficulty initiating movement.
  evidence:
  - reference: PMID:11756577
    supports: SUPPORT
    snippet: &gt;-
      Eleven patients who received immune globulin became able to walk more
      easily or without assistance
    explanation: &gt;-
      The improvement in walking ability after treatment indicates gait
      disturbance is a significant feature of the disease.
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
- category: Neurological
  name: Lumbar Hyperlordosis
  frequency: FREQUENT
  notes: &gt;-
    Exaggerated lumbar curvature due to continuous contraction of paraspinal
    muscles. May lead to ankylosing deformity.
  evidence:
  - reference: PMID:37059468
    supports: SUPPORT
    snippet: &gt;-
      stiffness in the truncal and proximal limb muscles, gait dysfunction, and
      episodic painful muscle spasms
    explanation: &gt;-
      Truncal muscle stiffness leads to the characteristic lumbar hyperlordosis
      posture in SPS patients.
  phenotype_term:
    preferred_term: Hyperlordosis
    term:
      id: HP:0003307
      label: Hyperlordosis
- category: Neurological
  name: Frequent Falls
  frequency: FREQUENT
  notes: &gt;-
    Result from impaired postural reflexes, stiff gait, and sudden spasms.
    Falls occur without protective reflexes due to rigidity.
  evidence:
  - reference: PMID:37059468
    supports: SUPPORT
    snippet: &gt;-
      stiffness in the truncal and proximal limb muscles, gait dysfunction, and
      episodic painful muscle spasms
    explanation: &gt;-
      Gait dysfunction and sudden muscle spasms predispose SPS patients to
      frequent falls.
  phenotype_term:
    preferred_term: Frequent falls
    term:
      id: HP:0002359
      label: Frequent falls
- category: Psychiatric
  name: Anxiety
  frequency: FREQUENT
  notes: &gt;-
    Severe chronic anxiety is common, often with task-specific phobias
    such as fear of crossing streets or open spaces. Not merely
    psychological but reflects heightened neuronal excitability.
  evidence:
  - reference: PMID:37059468
    supports: SUPPORT
    snippet: &gt;-
      the challenges in distinguishing the conditioning effects or expectations
      of chronically applied therapies from objective meaningful clinical benefits
    explanation: &gt;-
      Task-specific phobias and anxiety are recognized clinical features
      complicating assessment of treatment effects in SPS.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
biochemical:
- name: Anti-GAD65 Antibodies
  presence: Elevated
  context: &gt;-
    Very high titers (often &gt;10,000 IU/mL) in serum and CSF are diagnostic.
    Lower titers occur in type 1 diabetes without neurological disease.
  evidence:
  - reference: PMID:3281011
    supports: SUPPORT
    snippet: &gt;-
      A band comigrating with glutamic acid decarboxylase in sodium dodecyl
      sulfate-polyacrylamide gels appeared to be the only nervous-tissue
      antigen recognized by cerebrospinal fluid antibodies
    explanation: &gt;-
      This paper first identified GAD antibodies in stiff person syndrome.
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      Very high serum anti-GAD antibody titers are a key diagnostic feature
      for all GAD-SD
    explanation: &gt;-
      High-titer GAD antibodies are a diagnostic criterion.
- name: Anti-Amphiphysin Antibodies
  presence: Present
  context: &gt;-
    Found in approximately 5% of cases, often associated with paraneoplastic
    presentation, particularly breast cancer.
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      three other autoantibodies, against glycine receptors, amphiphysin and
      gephyrin, are less frequently or rarely associated with SPS-SD
    explanation: &gt;-
      Anti-amphiphysin antibodies are recognized as associated with SPS-SD.
- name: Anti-Glycine Receptor Antibodies
  presence: Present
  context: &gt;-
    Found in approximately 10-12% of SPS patients, particularly those with
    PERM. Unlike anti-GAD antibodies, these target extracellular epitopes
    and have demonstrated pathogenicity.
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      three other autoantibodies, against glycine receptors, amphiphysin and
      gephyrin, are less frequently or rarely associated with SPS-SD
    explanation: &gt;-
      Anti-glycine receptor antibodies are part of the SPS-spectrum disorders.
- name: CSF GABA Levels
  presence: Decreased
  context: &gt;-
    Reduced GABA levels in cerebrospinal fluid reflect impaired GABA
    synthesis due to GAD inhibition.
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      Very high serum anti-GAD antibody titers are a key diagnostic feature
      for all GAD-SD, commonly associated with the presence of GAD antibodies
      in the CSF, a reduced CSF GABA level
    explanation: &gt;-
      Reduced CSF GABA is documented in association with high GAD antibodies.
genetic:
- name: HLA-DRB1
  association: Associated
  notes: &gt;-
    Association with certain HLA class II alleles suggests genetic
    susceptibility to autoimmunity, though SPS itself is not inherited.
    The DQB1*0201 allele is present in approximately 70% of SPS patients.
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      In spite of the unique clinical phenotype that each of these disorders
      has, there is significant overlapping symptomatology characterized by
      autoimmune neuronal excitability
    explanation: &gt;-
      The shared autoimmune basis across GAD-spectrum disorders implies
      common genetic susceptibility factors including HLA associations.
treatments:
- name: Benzodiazepines
  description: &gt;-
    First-line symptomatic therapy. GABA-A receptor agonists that enhance
    GABAergic inhibition to reduce stiffness and spasms. Diazepam is most
    commonly used, starting at 5-10mg twice daily.
  evidence:
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      details on symptomatic GABA-enhancing drugs and the currently available
      immunotherapies in a step-by-step approach
    explanation: &gt;-
      Benzodiazepines are established as first-line symptomatic GABA-enhancing
      therapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Baclofen
  description: &gt;-
    GABA-B receptor agonist used for spasticity control. Often used when
    benzodiazepines are insufficient or poorly tolerated. Can be given
    orally or intrathecally for refractory cases.
  evidence:
  - reference: PMID:37059468
    supports: SUPPORT
    snippet: &gt;-
      combination therapies with the preferred gamma-aminobutyric
      acid-enhancing antispasmodic drugs, such as baclofen, tizanidine,
      benzodiazepines, and gabapentin
    explanation: &gt;-
      Baclofen is listed as a preferred GABA-enhancing antispasmodic drug
      for symptomatic treatment of SPS.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Intravenous Immunoglobulin
  description: &gt;-
    Immunomodulatory therapy that significantly reduces stiffness scores
    and improves mobility. Administered as 2g/kg divided over 2-5 days
    with monthly maintenance of 1g/kg. First-line immunotherapy effective
    in up to 75% of patients.
  evidence:
  - reference: PMID:11756577
    supports: SUPPORT
    snippet: &gt;-
      Among patients who received immune globulin first, stiffness scores
      decreased significantly (P=0.02)
    explanation: &gt;-
      Randomized controlled trial demonstrated significant efficacy of IVIg.
  - reference: PMID:11756577
    supports: SUPPORT
    snippet: &gt;-
      Intravenous immune globulin is a well-tolerated and effective, albeit
      costly, therapy for patients with stiff-person syndrome and anti-GAD65
      antibodies.
    explanation: &gt;-
      The trial conclusion establishes IVIg as effective treatment.
  - reference: PMID:37059468
    supports: SUPPORT
    snippet: &gt;-
      detailing the application of current immunotherapies with intravenous
      immunoglobulin (IVIg) plasmapheresis, and rituximab
    explanation: &gt;-
      The 2023 review confirms IVIg as a key immunotherapy option in the
      treatment algorithm.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Rituximab
  description: &gt;-
    Anti-CD20 monoclonal antibody that depletes B cells. Used as
    second-line immunotherapy when IVIg fails. Targets peripheral B-cell
    sources of autoantibodies. Dosing is empirical, typically 1-2g every
    6-12 months.
  evidence:
  - reference: PMID:37059468
    supports: SUPPORT
    snippet: &gt;-
      detailing the application of current immunotherapies with intravenous
      immunoglobulin (IVIg) plasmapheresis, and rituximab
    explanation: &gt;-
      Rituximab is included as part of the current immunotherapy options
      for SPS treatment.
  - reference: PMID:35084720
    supports: SUPPORT
    snippet: &gt;-
      focuses on therapies providing details on symptomatic GABA-enhancing
      drugs and the currently available immunotherapies in a step-by-step
      approach
    explanation: &gt;-
      Rituximab is part of the step-by-step therapeutic approach for
      refractory cases.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
disease_term:
  preferred_term: stiff-person syndrome
  term:
    id: MONDO:0008491
    label: stiff-person syndrome
classifications:
  harrisons_chapter:
  - classification_value: nervous system disorder
  - classification_value: autoimmune disease
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Stiff_Person_Syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>